Can Aging Knee Cartilage Be Rejuvenated?

Leon Wirz
12 minutes ago
6 min read

Science, November 2025 | Stanford University

Introduction

Osteoarthritis is one of the most common chronic diseases worldwide and a leading cause of pain, disability, and reduced mobility. It affects hundreds of millions of people globally and becomes increasingly common with age. For decades, the disease has largely been viewed as a consequence of mechanical wear and tear: cartilage gradually erodes, joints become inflamed, and eventually many patients require joint replacement surgery.

This view has shaped treatment strategies for years. Most available therapies focus on symptom management rather than reversing the disease itself. Painkillers, anti-inflammatory medications, physical therapy, and joint injections can improve quality of life, but none fundamentally restore damaged cartilage. When symptoms become severe, knee or hip replacement often becomes the final option.

A study published in Science by researchers at Stanford University challenges some of the basic assumptions underlying osteoarthritis. Rather than viewing cartilage degeneration as an irreversible consequence of aging, the researchers propose that aging cartilage may be actively maintained in a dysfunctional state by specific molecular pathways. Most importantly, they demonstrate that blocking one age-associated enzyme can regenerate cartilage in mice and improve human osteoarthritic cartilage samples in the laboratory.

The findings suggest that osteoarthritis may not simply be a disease of accumulated wear. At least in part, it may be a disease of biological aging.

The Core Discovery

The focus of the study is an enzyme called 15-hydroxyprostaglandin dehydrogenase (15-PGDH).

This enzyme degrades prostaglandins (signaling molecules involved in tissue maintenance, repair, and regeneration). Previous research from the same group had shown that 15-PGDH increases in several aging tissues, including skeletal muscle, where it contributes to age-related functional decline.

The researchers discovered that 15-PGDH is also elevated in aging and injured cartilage. In aged mouse cartilage, levels were approximately twice as high as in young animals. Similar increases were observed following knee injuries that lead to osteoarthritis.

When the researchers inhibited 15-PGDH using a small molecule called SW033291, they observed substantial cartilage regeneration. Importantly, the regenerated tissue displayed characteristics of healthy hyaline cartilage (the smooth, durable cartilage that normally covers joint surfaces) rather than inferior fibrocartilage (a tougher but less functional repair tissue often formed after injury).

Perhaps even more surprising was the mechanism. Regeneration did not appear to rely on stem cells or the expansion of progenitor cell populations. Instead, existing cartilage cells underwent a shift toward a more youthful state, suggesting that aging cartilage may retain a previously unrecognized capacity for repair.

How the Study Was Conducted

The investigators used several complementary approaches.

First, they examined cartilage from young and aged mice and measured 15-PGDH expression. They then treated aged mice with a 15-PGDH inhibitor for one month and evaluated cartilage structure using histological analyses.

To study injury-induced osteoarthritis, the team used a mouse model that mimics anterior cruciate ligament (ACL) rupture, a common sports injury associated with later osteoarthritis development. Following injury, mice received local injections of the inhibitor directly into the knee joint.

The researchers also performed advanced single-cell RNA sequencing and multiplex imaging techniques to identify individual cartilage cell populations and track how these populations changed during aging and treatment.

Finally, they obtained cartilage samples from patients undergoing knee replacement surgery. These human osteoarthritis tissues were treated with the inhibitor in laboratory culture systems to determine whether similar biological effects could be observed in human cells.

Key Findings

The results were notable across multiple experimental systems.

In aged mice, inhibition of 15-PGDH led to:

Increased cartilage thickness
Higher proteoglycan content
Increased collagen type II expression
Lower osteoarthritis damage scores
Restoration of cartilage architecture resembling younger tissue

In mice with post-traumatic osteoarthritis following ACL injury, treatment reduced cartilage degeneration, decreased inflammatory markers, and improved measures of pain and mobility.

One of the most interesting findings emerged from the single-cell analyses. The researchers identified a population of cartilage cells that accumulated with aging and injury. These cells expressed high levels of 15-PGDH and molecular markers associated with cartilage hypertrophy, ossification, and tissue degeneration.

Following treatment, these dysfunctional cell populations declined, while healthy extracellular matrix-producing chondrocytes expanded.

This suggests that cartilage regeneration occurred not because new cells were created, but because existing cells changed their biological behavior.

Human cartilage samples showed encouraging results as well. After treatment, osteoarthritic cartilage demonstrated:

Increased glycosaminoglycan content
Improved cartilage stiffness
Reduced activity of 15-PGDH
Reduced abundance of degeneration-associated chondrocytes
Evidence of improved extracellular matrix production

Although these findings were generated outside the body in tissue cultures, they provide an important indication that the biological mechanisms may also be relevant in humans.

Limitations of the Study

Despite the excitement surrounding the findings, several important limitations should be acknowledged.

The strongest evidence comes from mouse models. While mice are valuable tools for studying osteoarthritis, many therapies that perform well in animals ultimately fail in human clinical trials.

The human component of the study was limited to cartilage explants obtained during knee replacement surgery. Although these experiments demonstrated biological effects, they do not show that cartilage regeneration can occur within living patients.

The long-term safety of 15-PGDH inhibition also remains unclear. Prostaglandins influence numerous physiological processes throughout the body, including inflammation, blood flow, and tissue repair. Chronic inhibition of 15-PGDH could potentially produce unintended consequences that were not detectable in these short-term experiments.

Finally, it remains uncertain whether regenerated cartilage would remain stable for years or whether osteoarthritis progression would eventually resume.

Relevance for Switzerland

The implications of this research are particularly relevant for Switzerland's aging population.

Osteoarthritis is one of the major drivers of musculoskeletal disability and contributes substantially to healthcare expenditures. Thousands of Swiss patients undergo knee and hip replacement procedures every year, generating significant costs for healthcare providers, insurers, and rehabilitation services.

A therapy capable of slowing, preventing, or even partially reversing cartilage degeneration could reduce the burden associated with joint replacement surgery and long-term pain management.

Such treatments could also help older adults remain physically active for longer periods, potentially reducing secondary health problems associated with inactivity, including obesity, cardiovascular disease, and loss of independence.

Potential Impacts of a Successful Therapy

If future human trials confirm these findings, the implications could be substantial.

Rather than simply masking symptoms, osteoarthritis treatment could move toward true disease modification.

Potential benefits might include:

Delayed or avoided joint replacement surgeries
Improved mobility in older adults
Reduced chronic pain
Lower healthcare costs
Increased healthy lifespan and independence

Perhaps most importantly, the study introduces the possibility that aging tissues can be rejuvenated by targeting specific molecular drivers of aging rather than replacing the tissue altogether.

This concept extends beyond cartilage and could influence future approaches to age-related diseases in multiple organs.

Risks

As with all regenerative therapies, caution is warranted.

Prostaglandin signaling plays complex roles throughout the body. Increasing prostaglandin activity may produce unintended effects depending on tissue type, dosage, and duration of treatment.

Researchers will need to determine:

The optimal dose and delivery method
Long-term safety profiles
Potential effects on other organs
Whether benefits persist after treatment ends
Which patients are most likely to respond

It is also possible that the therapy may be more effective during early disease stages than in advanced osteoarthritis.

Overall Assessment

This study represents one of the most compelling osteoarthritis papers published in recent years.

Its significance lies not only in the regeneration observed, but also in the conceptual shift it introduces. Rather than viewing osteoarthritis purely as the result of irreversible mechanical damage, the findings suggest that age-related molecular programs actively maintain cartilage degeneration.

By targeting one of these programs, the researchers were able to push aging cartilage toward a younger biological state.

The work remains preclinical, and considerable uncertainty remains before clinical application becomes realistic. Nevertheless, the combination of mechanistic depth, robust animal data, advanced single-cell analyses, and supportive findings in human cartilage makes this one of the most promising regenerative approaches currently under investigation.

What Comes Next

The next critical step will be human clinical trials.

Researchers must determine whether 15-PGDH inhibition can safely regenerate cartilage and improve symptoms in patients with osteoarthritis.

Future studies will likely focus on:

Early-stage osteoarthritis patients
Optimal local versus systemic delivery methods
Long-term durability of cartilage regeneration
Biomarkers that identify responders
Combination strategies with existing regenerative therapies

If successful, this work could represent the beginning of a new generation of osteoarthritis treatments aimed not at replacing joints, but at rejuvenating them.

Reference

Singla M, Wang YX, Monti E, Bedi Y, Agarwal P, Su S, Ancel S, Hermsmeier M, Devisetti N, Pandey A, Bakooshli MA, Palla AR, Goodman S, Blau HM, Bhutani N.

Inhibition of 15-hydroxy prostaglandin dehydrogenase promotes cartilage regeneration.

Science. 2026 Mar 5;391(6789):1053-1062. doi: 10.1126/science.adx6649. Epub 2025 Nov 27. PMID: 41308124; PMCID: PMC13127300. Link